Atopic dermatitis was associated with the greatest burden of disease compared with 2 other types of dermatitis, in which high incidence and disability-adjusted life-years rates corresponded with high sociodemographic index areas.
Burden of dermatitis was substantially greater in patients with atopic vs contact and seborrheic disease, with high sociodemographic index (SDI) indicators found to correspond with high incidence and disability-adjusted life-years (DALYs) rates.
Results were published in Frontiers in Cellular and Infection Microbiology.
Among skin diseases, dermatitis ranks first in global disease burden, consisting of adverse social ability and physical/mental health, as well as economic implications. The 3 main types of dermatitis are atopic dermatitis (AD), contact dermatitis (CD), and seborrheic dermatitis (SD); AD has been associated with the greatest global burden.
“Health problems or distress caused by dermatitis may be easily overlooked, and relevant epidemiological data are limited…currently, research on the socioeconomic relationship between AD, CD, and SD in the global burden of disease is lacking,” noted the study authors. “Therefore, a better understanding of the burden of dermatitis is necessary for developing global intervention strategies.”
Leveraging the Global Burden of Disease (GBD) 2019 database, they investigated the age-standardized incidence rate (ASIR) and the DALYs rate (ASDR) data of patients with AD, CD, and SD. Data were stratified by sex, country or region, and SDI indicators. The correlation between the global burden of dermatitis and socioeconomic development status was also examined.
“[SDI] is the geometric mean of the normalized value of the regional per capita income, the number of years of education of those 15 years old and above, and the total fertility rate of women under 25,” they explained. “GBD 2019 divides countries into 5 categories based on SDI indicators: high SDI, high-middle SDI, middle SDI, low-middle SDI, and low SDI.”
Overall, GBD 2019 estimates on the ASIR and ASDR per 100,000 person-years for the 3 major types of dermatitis were 5244.3988 (95% CI, 4551.7244-5979.3176) and 131.6711 (95% CI, 77.5876-206.8796), respectively.
The rates were exhibited for each type of dermatitis, with the greatest burden associated with AD:
The researchers additionally measured changes in the burden of dermatitis from 1990 to 2019, in which a slow downward trend was observed in recent years according to ASDR data. By country/region in 2019, the ASIR showed that the United States had the greatest burden, whereas the ASDR showed that Asian countries (such as Japan, Mongolia, Kazakhstan, and Uzbekistan) and some European countries (France, Estonia) had the greatest burden.
SDI stratification regarding the 3 major dermatitis types further showed that high ASIR and ASDR corresponded with high SDI areas, especially for AD, which was positively correlated with the SDI.
“The results based on GBD 2019 data are valuable for formulating policy; preventing and treating dermatitis; and reducing the global burden of dermatitis,” concluded the researchers.
Reference
Xue Y, Bao W, Zhou J, et al. Global burden, incidence and disability-adjusted life-years for dermatitis: a systematic analysis combined with socioeconomic development status, 1990–2019. Front Cell Infect Microbiol. Published online April 12, 2022. doi:10.3389/fcimb.2022.861053
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
Real-World Study Reveals Key Insights Into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More